JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders

Leukemia

Volumn 20, Issue 3, 2006, Pages 471-476

  Quentmeier, H ^a   MacLeod, R A F ^a   Zaborski, M ^a   Drexler, H G ^a  

^a LEIBNIZ INSTITUTE DSMZ GERMAN COLLECTION OF MICROORGANISMS AND CELL CULTURES   (Germany)

Author keywords

HEL; JAK2; MB 02; MUTZ 8; SET 2; UKE 1

Indexed keywords

JANUS KINASE 2; MICROSATELLITE DNA; PROTEIN TYROSINE KINASE;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL GROWTH; CELL LINE; CHROMOSOME 5Q; CHROMOSOME 7Q; CHROMOSOME 9P; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CYTOGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; KARYOTYPING; MITOTIC RECOMBINATION; MUTANT; MYELOPROLIFERATIVE DISORDER; PATHOGENESIS; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; WILD TYPE;

EID: 33644546402     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404081     Document Type: Article

References (22)

1. Baxter EJ, Scott LM, Campbell PJ. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.
2. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJP et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thromobocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387-397.
3. James C, Ugo V, LeCouedic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-1148.
4. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790.
5. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005; 106: 2162-2168.
6. Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia-chromosome negative CML and megakaryocytic leukemia. Blood 2005; 106: 3370-3373.
7. Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both 'atypical' myeloproliferative disorders and the myelodysplastic syndrome. Blood 2005; 106: 1207-1209.
8. Levine RL, Loriaux M, Huntly BJP, Loh ML, Beran M, Stoffregen E et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 2005; 106: 3377-3379.
9. Parganas E, Wang D, Stravopodis D, Topham DJ, Marine JC, Teglund S et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998; 93: 385-395.
10. Peeters P, Raynaud SD, Cools J, Wlodarska I, Grosgeorge J, Philip P et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 1997; 90: 2535-2540.
11. Nunez CA, Zipf TF, Roberts WM, Medeiros LJ, Hayes K, Bueso-Ramos CE. Molecular monitoring of cerebrospinal fluid can predict clinical relapse in acute lymphoblastic leukemia with eosinophilia. Arch Pathol Lab Med 2003; 127: 601-605.
12. Reiter A, Walz C, Watmore A, Schoch C, Blau I, Schlegelberger B et al. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res 2005; 65: 2662-2667.
13. Drexler HG, Dirks W, MacLeod RAF, Quentmeier H, Steube KG, Uphoff CC. DSMZ Catalogue of Human and Animal Cell Lines, 8th edn. DSMZ: Braunschweig, Germany, 2001.
14. Drexler HG. The Leukemia-Lymphoma Cell Line Factsbook. Academic Press: San Diego, CA, 2000.
15. MacLeod RAF, Drexler HG. Cytogenetic analysis of cell lines. Methods Mol Biol 2005; 290: 51-70.
16. Quentmeier H, Martelli MP, Dirks WG, Bolli N, Liso A, MacLeod RAF et al. Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin. Leukemia 2005; 19: 1760-1767.
17. Quentmeier H, Zaborski M, Drexler HG. Effects of thrombopoietin, interleukin-3 and the kinase inhibitor K-252a on growth and polyploidization of the megakaryocytic cell line M-07e. Leukemia 1998; 12: 1603-1611.
18. Hu ZB, MacLeod RAF, Meyer C, Quentmeier H, Drexler HG. New acute myeloid leukemia-derived cell line: MUTZ-8 with 5q-. Leukemia 2002; 16: 1556-1561.
19. Uozumi K, Otsuka M, Ohno N, Moriyama T, Suzuki S, Shimotakahara S et al. Establishment and characterization of a new human megakaryoblastic cell line (SET-2) that spontaneously matures to megakaryocytes and produces platelet-like particles. Leukemia 2000; 14: 142-152.
20. Fiedler W, Henke RP, Ergün S, Schumacher U, Gehling UM, Vohwinkel G et al. Derivation of a new hematopoietic cell line with endothelial features from a patient with transformed myeloproliferative syndrome. Cancer 2000; 88: 344-351.
21. Charrin C. del(5q) in myeloid malignancies. Atlas Genet Cytogenet Oncol Haematol 1998, URL: http://www.infobiogen.fr/services/chromcancer/ Anomalies/del5qID1092.html.
22. MacLeod RAF, Dirks WG, Reid YA, Hay RJ, Drexler HG. Identity of original and late passage Dami megakaryocytes with HEL erythroleukemia cells shown by combined cytogenetics and DNA fingerprinting. Leukemia 1997; 11: 2032-2038.